ICCC - NASDAQ
ImmuCell Corporation
$9.79
-1.8%ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
At a Glance
Live SnapshotImmuCell Corporation Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ImmuCell Corporation Income Statement
ICCC • NASDAQ
| ImmuCell Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
27.6M | 26.5M | 17.5M | 18.6M | 19.2M | 15.3M | 13.7M | 11M | 10.4M | 9.5M | 10.2M | 7.6M | 6M | 5.4M | 5.1M | 4.4M | 4.5M | 4.6M | 6.1M | 4.8M | |
GROSS PROFIT | ||||||||||||||||||||
(16.2M) | (18.6M) | (13.1M) | (10.9M) | (10.6M) | (8.5M) | (7M) | (5.8M) | (5.2M) | (4.1M) | (4M) | (3.1M) | (2.9M) | (2.3M) | (2.3M) | (2.1M) | (2.1M) | (2.6M) | (2.3M) | (1.9M) | |
11.4M | 7.9M | 4.4M | 7.6M | 8.7M | 6.9M | 6.7M | 5.2M | 5.2M | 5.4M | 6.3M | 4.4M | 3.1M | 3.1M | 2.8M | 2.3M | 2.4M | 2.1M | 3.8M | 2.9M | |
OPERATING INCOME | ||||||||||||||||||||
(9.8M) | (9.6M) | (10.1M) | (9.9M) | (8.4M) | (8.2M) | (7.7M) | (7.3M) | (5.5M) | (4.5M) | (4.1M) | (4.7M) | (3.1M) | (2.8M) | (3.4M) | (3M) | (2.9M) | (3.2M) | (2.9M) | (2.1M) | |
(6.8M) | (5.7M) | (5.2M) | (5.5M) | (4.2M) | (3.9M) | (4M) | (3.8M) | (3.4M) | (3.3M) | (2.9M) | (2.5M) | (1.9M) | (1.9M) | (1.7M) | (1.5M) | (1.3M) | (1.5M) | (1.3M) | (1.2M) | |
(3M) | (3.9M) | (4.4M) | (4.5M) | (4.2M) | (4.4M) | (3.7M) | (3.5M) | (2M) | (1.2M) | (1.2M) | (2.2M) | (1.2M) | (917.6K) | (1.7M) | (1.5M) | (1.6M) | (1.7M) | (1.6M) | (965.9K) | |
1.6M | -1.6M | -5.7M | -2.3M | 257.4K | -1.4M | -954K | -1.4M | -243K | 890.2K | 2.1M | -206.4K | -19.6K | 245K | -632.7K | -690.3K | -527K | -1.2M | 872.1K | 770.7K | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (568.7K) | (0.0) | (348.5K) | (314.4K) | (412.7K) | (431.8K) | (427.8K) | (218.6K) | (161.7K) | (83.6K) | (60.7K) | (69.6K) | (78.2K) | (81K) | (22K) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -491K | 0.0 | -195.4K | -295.5K | -385.2K | -311K | -413.5K | -201.7K | -107K | -64.4K | -45.2K | -57.1K | -60.9K | -71.1K | 982.0 | 96K | 204.5K | 0.0 | 0.0 | |
(0.0) | (0.0) | (527K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -24.8K | (5.6K) | -3.9K | (0.0) | (8.1K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.7M | -506.4K | -21.9K | -186.8K | -326.5K | 347.9K | -313.5K | -413.5K | -195.6K | -131.9K | -58.8K | -49.1K | 224.8K | -52.8K | -64K | 6.9K | 98.5K | 206.9K | 271.5K | 263.4K | |
-1M | -2.1M | -5.8M | -2.5M | -69.1K | -1M | -1.3M | -1.9M | -438K | 758.3K | 2.1M | -255.5K | 205.3K | 192.2K | -696.7K | -683.4K | -428.5K | -960.7K | 1.1M | 1M | |
NET INCOME | ||||||||||||||||||||
(11K) | (10.1K) | (4.6K) | (8K) | (9.2K) | -10K | (28K) | (462K) | -270K | (249.9K) | (850.3K) | -88.3K | (87.9K) | (102.6K) | -287.2K | -298.7K | -212K | -492.1K | (481.5K) | (386.9K) | |
-1M | -2.2M | -5.8M | -2.5M | -78.3K | -1M | -1.3M | -2.3M | -168K | 508.4K | 1.2M | -167.2K | 117.4K | 89.5K | -409.5K | -384.7K | -216.5K | -468.6K | 662.1K | 647.1K |
SEC Filings
ICCC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | May 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 08, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 |
Related Guides
Continue your ICCC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.